Aprotinin

International Anesthesiology Clinics

Volumn 42, Issue 4, 2004, Pages 81-91

  Alston, Theodore A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; APROTININ; HEPARIN; KALLIKREIN; NAFAMSTAT; PLASMIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBOMODULIN; TRYPSIN INHIBITOR; ULINASTATIN;

ANAPHYLAXIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; DOSE CALCULATION; DRUG MECHANISM; DRUG STRUCTURE; HEMOSTASIS; HUMAN; KIDNEY DYSFUNCTION; PARTIAL THROMBOPLASTIN TIME; PEDIATRIC ANESTHESIA; PRIORITY JOURNAL; REVIEW;

ANTICOAGULANTS; APROTININ; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; HEMOSTATICS; HEPARIN; HUMANS;

EID: 6344227858     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-200404240-00009     Document Type: Review

References (84)

1. Kunitz M, Northrop JH. Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor, and an inhibitor-trypsin compound. J Gen Physiol. 1938;19: 991-1007.
2. Kraut H, Frey EK, Werle E. Regarding the inactivation of the kallikreins. Hoppe-Seyler's Z. Physiol Chem. 1930;192:1-21.
3. Kassell B. Bovine trypsin-kallikrein inhibitor (Kunitz inhibitor, basic pancreatic trypsin inhibitor, polyvalent inhibitor from bovine organs). Methods Enzymol. 1970;19:844-852.
4. Cardigan RA, Mackie IJ, Gippner-Steppert C, et al. Determination of plasma aprotinin levels by functional and immunologic assays. Blood Coagul Fibrinolysis. 2001;12:37-42.
5. Patston PA, Gettins PG, Schapira M. Serpins are suicide substrates: implications for the regulation of proteolytic pathways. Semin Thromb Hemost. 1994;20:410-416.
6. Engh RA, Huber R, Bode W, et al. Divining the serpin inhibition mechanism: a suicide substrate "springe"? Trends Biotechnol. 1995;13:503-510.
7. Hermans JM, Monard D, Jones R, et al. Inhibition of acrosin by serpins. A suicide substrate mechanism. Biochemistry. 1995;34:3678-365.
8. Jansen EF, Balls AK. The inhibition of β- and γ-chymotrypsin and trypsin by diisopropyl fluorophosphates. J Biol Chem. 1952;194:721-727.
9. Schaffer NK, May SC Jr, Summerson WH. Serine phosphoric acid from diisopropylphosphoryl chymotrypsin. J Biol Chem. 1953;202:67-76.
10. Rezaie AR, He X, Esmon CT. Thrombomodulin increases the rate of thrombin inhibition by BPTI. Biochemistry. 1998;37:693-699.
11. Werle E. Regarding the activity of the kallikreins of the pancreas and its external secretions in the dog. Biochem Z. 1937;290:129-134.
12. Werle E, Götze W, Keppler A. Regarding the effect of the kallikreins on the isolated intestine and regarding a new intestine contracting substance. Biochem Z. 1937;289: 217-233.
13. Colman RW, Mattler L, Sherry S. Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasm. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest. 1969;48:23-32.
14. Girey GJ, Talamo RC, Colman RW. The kinetics of the release of bradykinin by kallikrein in normal human plasma. J Lab Clin Med. 1972;80:496-505.
15. MacFarlane RG, Biggs R. Fibrinolysis. Its mechanism and significance. Blood. 1948;3: 1167-1187.
16. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med. 1933;58:485-502.
17. Marten J. Trasylol in the treatment of acute infantile pancreatitis. Cesk Pediatr. 1969;24: 458-461.
18. Ritter R. The treatment of Waterhouse-Friderichsen syndrome (in meningococcal sepsis) with Trasylol. Munch Med Wochenschr. 1967;109:2238-2242.
19. Ambrus JL, Ambrus CM, Stutzman L, et al. Treatment of fibrinolytic hemorrhage with proteinase inhibitors: a preliminary report. Ann N Y Acad Sci. 1968;146:625-641.
20. Alebouyeh M, Remien A, Marget W. Incidence of disseminated intravascular coagulation in the course of septicemia in newborn infants. Z Kinderheilkd. 1971;109: 326-332.
21. Sitkovskii NB, Kutsenko TA, Khanes GB, et al. Use of proteolytic enzyme inhibitors in the complex treatment of septic diseases in children. Klin Khir. 1972;8:49-53.
22. Laursen B, Faber V, Brock A, et al. Disseminated intravascular coagulation, anti-thrombin III, and complement in meningococcal infections. Acta Med Scand. 1981;209: 221-227.
23. Gans H, Castaneda AR, Subramanian V, et al. Problems in hemostasis during open heart surgery. IX. Changes observed in the plasminogen-plasmin system and their significance for therapy. Ann Surg. 1967;166:980-986.
24. Gans H, Subramanian V, John S, et al. Theoretical and practical (clinical) considerations concerning proteolytic enzymes and their inhibitors with particular reference to changes in the plasminogen-plasmin system observed during assisted circulation in man. Ann N Y Acad Sci. 1968;146:721-736.
25. Urban AE, Popov-Cenic S, Noe G, et al. Aprotinin in open-heart surgery of infants and children using the heart-lung machine. Clin Ther. 1984;6:425-433.
26. Nagaoka H, Katori M. Inhibition of kinin formation by a kallikrein inhibitor during extracorporeal circulation in open-heart surgery. Circulation. 1975;52:325-332.
27. McMichan JC, Rosengarten DS, Philipp E. Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin: a clinical study. Circ Shock. 1982;9:107-116.
28. Royston D, Bidstrup BP, Taylor KM, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2:1289-1291.
29. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 1987;44:640-645.
30. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth. 1992;6:76-100.
31. Royston D. Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid. Int Anesthesiol Clin. 1995;33:155-179.
32. Boldt J, Knothe C, Zickmann B, et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg. 1993;105:705-711.
33. Rentoul TM, Harrison VL, Shun A. The effect of aprotinin on transfusion requirements in pediatric orthotopic liver transplantation. Pediatr Transplant. 2003;7:142-148.
34. Cole JW, Murray DJ, Snider RJ, et al. Aprotinin reduces blood loss during spinal surgery in children. Spine. 2003;28:2482-2485.
35. Khoshhal K, Mukhtar I, Clark P, et al. Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. J Pediatr Orthop. 2003;23:661-664.
36. D'Errico CC, Munro HM, Buchman SR, et al. Efficacy of aprotinin in children undergoing craniofacial surgery. J Neurosurg. 2003;99:287-290.
37. Costello JM, Backer CL, de Hoyos A, et al. Aprotinin reduces operative closure time and blood product use after pediatric bypass. Ann Thorac Surg. 2003;75:1261-1266.
38. Mossinger H, Dietrich W, Braun SL, et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg. 2003;75:430-437.
39. Chauhan S, Kumar BA, Rao BH, et al. Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease. Ann Thorac Surg. 2000;70:1308-1312.
40. Wippermann CF, Schmid FX, Eberle B, et al. Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. Ann Thorac Surg. 1999;67:173-176.
41. Miller BE, Tosone SR, Tam VK, et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg. 1998;66:535-540.
42. Carrel TP, Schwanda M, Vogt PR, et al. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg. 1998;66:153-158.
43. Mossinger H, Dietrich W. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Ann Thorac Surg. 1998;65(suppl 6):S45-S50.
44. Coniff RF. The Bayer 022 compassionate-use pediatric study. Ann Thorac Surg. 1998; 65(suppl 6):S31-S33.
45. Davies MJ, Allen A, Kort H, et al. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Ann Thorac Surg. 1997;63:497-503.
46. D'Errico CC, Shayevitz JR, Martindale SJ, et al. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg. 1996;83:1193-1199.
47. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardio-pulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg. 1993;105:712-720.
48. D'Errico CC, Munro HM, Bove EL. Pro: the routine use of aprotinin during pediatric cardiac surgery is a benefit. J Cardiothorac Vasc Anesth. 1999;13:782-784.
49. Williams GD, Ramamoorthy C. Con: the routine use of aprotinin during pediatric cardiac surgery is not a benefit. J Cardiothorac Vasc Anesth. 1999;13:785-788.
50. Ranucci M, Corno A, Pavesi M, et al. Renal effects of low dose aprotinin in pediatric cardiac surgery. Minerva Anestesiol. 1994;60:361-366.
51. Ryckwaert Y, Barthelet Y, Bonnet-Boyer MC, et al. Anaphylactic shock after a test-dose of aprotinin in pediatric orthopedic surgery. Ann Fr Anesth Reanim. 1999;18:904-908.
52. Jaquiss R, Ghanayem N, Zacharisen M, et al. Safety of aprotinin use and re-use in pediatric cardiothoracic surgery. Circulation. 2002;106(suppl):90-94.
53. Dietrich W, Spath P, Zuhlsdorf M, et al. Anaphylactic reactions to aprotinin reexposure in cardiac surgery: relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiology. 2001;95:64-71.
54. Dietrich W, Spath P, Ebell A, et al. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg. 1997;113:194-201.
55. Oswald AM, Joly LM, Gury C, et al. Fatal intraoperative anaphylaxis related to aprotinin after local application of fibrin glue. Anesthesiology. 2003;99:762-763.
56. Cohen DM, Noberto J, Cartabuke R, et al. Severe anaphylactic reaction after primary exposure to aprotinin. Ann Thorac Surg. 1999;67:837-838.
57. Wendel HP, Heller W, Gallimore MJ, et al. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis. 1993;4:41-45.
58. Dietrich W, Jochum M. Effect of celite and kaolin on activated clotting time in the presence of aprotinin: activated clotting time is reduced by binding of aprotinin to kaolin. J Thorac Cardiovasc Surg. 1995;109:107-108.
59. Alston TA. Adsorption of aprotinin by kaolin. Anesth Analg. 1995;80:SCA130.
60. D'Ambra MN, Alston TA. Is kaolin the ideal way to monitor anticoagulation with heparin in aprotinin-treated patients? In: Pifarre R, ed. Blood Conservation With Aprotinin. Philadelphia, PA: Hanley and Belfus; 1995:247-251.
61. Alston TA. Baggio RF. Aminocaproic acid enhances inactivation of plasmin by aprotinin. Anesth Analg. 1995;80:SCA129.
62. Ray MJ, Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost. 1997;78:1021-1026.
63. Alston TA. Procoagulant action of aprotinin. Anesth Analg. 1996;82:1305.
64. Linden MD, Schneider M, Erber WN. Factor V(LEIDEN) and cardiopulmonary bypass: investigation of haemostatic parameters and the effect of aprotinin using an ex vivo model. Perfusion. 2001;16:476-484.
65. Sweeney JD, Blair AJ, Dupuis MP, et al. Aprotinin, cardiac surgery, and factor V Leiden. Transfusion. 1997;37:1173-1178.
66. Robbins P, Forrest M, Fanning S, et al. Use of aprotinin therapy in a patient with factor V Leiden. Anesth Analg. 1997;84:694-698.
67. Sievert A, McCall M, Blackwell M, et al. Use of aprotinin during cardiopulmonary bypass in a patient with protein C deficiency. J Extra Corpor Technol. 2003;35:39-43.
68. Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64: 1057-1068.
69. Andersen H, Greenberg DL, Fujikawa K, et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA. 1999;96:11189-11193.
70. Jacques SL, LeMasurier M, Sheridan PJ, et al. Substrate-assisted catalysis of the PARI thrombin receptor. Enhancement of macromolecular association and cleavage. J Biol Chem. 2000;275:40671-40678.
71. Poullis M, Manning R, Laffan M, et al. The antithrombotic effect of aprotinin: actions mediated via the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2000;120: 370-378.
72. Landis RC, Haskard DO, Taylor KM. New anti-inflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg. 2001;72:S1808-S1813.
73. Pintingy D, Prigent DJ. Aprotinin can inhibit the proteolytic activity of thrombin: a fluorescent and enzymatic study. Eur J Biochem. 1992;207:89-95.
74. Sugita T, Watarida S, Katsuyama K, et al. Effect of a human urinary protease inhibitor (ulinastatin) on respiratory function in pediatric patients undergoing cardiopulmonary bypass. J Cardiovasc Surg (Torino). 2002;43:437-440.
75. Sato Y, Ishikawa S, Otaki A, et al. Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury. Jpn J Thorac Cardiovasc Surg. 2000;48:428-434.
76. Hiyama A, Takeda J, Kotake Y, et al. A human urinary protease inhibitor (ulinastatin) inhibits neutrophil extracellular release of elastase during cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997;11:580-584.
77. Kawamura T, Inada K, Akasaka N, et al. Ulinastatin reduces elevation of cytokines and soluble adhesion molecules during cardiac surgery. Can J Anaesth. 1996;43:456-460.
78. Nagaya M, Futamura M, Kato J, et al. Application of a new anticoagulant (nafamostat mesylate) to control hemorrhagic complications during extracorporeal membrane oxygenation - a preliminary report. J Pediatr Surg. 1997;32:531-535.
79. Nakamura K, Onitsuka T, Yano M, et al. Nafamostat mesilate treatment during open heart operation in immune thrombocytopenic purpura. Ann Thorac Surg. 2000;70: 2161-2163.
80. Kotani K, Ichiba S, Andou M, et al. Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation. J Thorac Cardiovasc Surg. 2002;124:626-627.
81. Nakamura K, Onitsuka T, Yano M, et al. Influence of heparin dosage under combined use of Nafamostat mesilate during deep hypothermic circulatory arrest. Jpn J Thorac Cardiovasc Surg. 2003;51:186-191.
82. Ramjee MK, Henderson IM, McLoughlin SB, et al. The kinetic and structural characterization of the reaction of nafamostat with bovine pancreatic trypsin. Thromb Res. 2000;98:559-569.
83. Nozawa M, Tanizawa K, Kanaoka Y. "Inverse substrates" for trypsin-like enzymes. J Pharmacobiodyn. 1980;3:213-219.
84. Thormann M, Thust S, Hofmann HJ, et al. Protease-catalyzed hydrolysis of substrate mimetics (inverse substrates): a new approach reveals a new mechanism. Biochemistry. 1999;38:6056-6062.